ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

“Mini-Transplantation” In Testing For Treatment Of Multiple Myeloma

January 25, 2002

Phase III Vaccine Trial Fails To Improve Overall Survival

October 25, 2013

The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

October 31, 2014

Panel Suggests Test Of Paid Advertising For ACS: Roundup

August 7, 1992

Taking on question of cost and outcomes, CMS turns to expert in cancer care quality.

June 3, 2005

Mammography’s Best Role Is Screening, Kopans Assert

March 18, 1994